Ramsay Stattman Vela & Price Inc. Sells 965 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Ramsay Stattman Vela & Price Inc. lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 11,229 shares of the medical equipment provider’s stock after selling 965 shares during the period. Ramsay Stattman Vela & Price Inc.’s holdings in Zimmer Biomet were worth $1,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of ZBH. North Star Investment Management Corp. grew its position in Zimmer Biomet by 16.6% in the 1st quarter. North Star Investment Management Corp. now owns 669 shares of the medical equipment provider’s stock worth $88,000 after purchasing an additional 95 shares during the last quarter. BLB&B Advisors LLC grew its position in Zimmer Biomet by 2.1% in the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after purchasing an additional 100 shares during the last quarter. PFG Advisors grew its position in Zimmer Biomet by 5.5% in the 1st quarter. PFG Advisors now owns 2,004 shares of the medical equipment provider’s stock worth $265,000 after purchasing an additional 105 shares during the last quarter. M&R Capital Management Inc. grew its position in Zimmer Biomet by 14.1% in the 3rd quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock worth $92,000 after purchasing an additional 105 shares during the last quarter. Finally, Mill Creek Capital Advisors LLC grew its position in Zimmer Biomet by 5.1% in the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 106 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several research analyst reports. Piper Sandler lowered shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $140.00 to $115.00 in a research report on Monday, July 1st. TD Cowen decreased their target price on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research report on Friday, September 6th. Evercore ISI decreased their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. UBS Group decreased their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research report on Thursday, August 8th. Finally, Morgan Stanley decreased their target price on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $123.94.

Zimmer Biomet Trading Up 0.7 %

Shares of ZBH traded up $0.77 on Tuesday, reaching $104.37. 351,080 shares of the company’s stock were exchanged, compared to its average volume of 1,469,412. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $21.47 billion, a P/E ratio of 22.42, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. The business has a 50 day moving average price of $107.45 and a two-hundred day moving average price of $111.19. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. Zimmer Biomet’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.82 earnings per share. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.97 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Monday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.